Heartbeam, Inc. (BEAT) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Heartbeam, Inc. on February 12, 2025, regarding events occurring on February 12 and February 14, 2025. The Company is an emerging growth company incorporated in Delaware, with principal executive offices in Santa Clara, California. The filing primarily addresses the entry into a material definitive agreement for a public equity offering.
Key Financial Metrics and Transaction Details
The filing details a firm commitment underwritten offering of common stock. Key transaction metrics include:
- Shares Issued: 5,882,353 shares of Common Stock.
- Public Offering Price: $1.70 per share.
- Gross Proceeds: Approximately $10 million (before deducting underwriting discounts, commissions, and offering expenses).
- Underwriter Warrants: 588,235 warrants issued to the underwriter (10% of shares sold), exercisable at $2.125 per share (125% of offering price).
- Warrant Terms: Exercisable starting February 9, 2026, expiring February 14, 2030.
The filing does not provide specific data on the Company's historical revenue, profit, cash flow, margins, or existing debt levels. Liquidity impact is limited to the gross proceeds from this specific offering.
Material Changes and Agreements
On February 12, 2025, the Company entered into an Underwriting Agreement with Public Ventures, LLC dba MDB Capital. The offering closed on February 14, 2025. Material terms include:
- Lock-Up Agreements: Directors and executive officers are restricted from selling securities for 180 days following the closing date.
- Issuance Restrictions: The Company is prohibited from issuing Common Stock or equivalents during the 180-day lock-up period (with certain exceptions) and from engaging in variable rate transactions for 12 months from the closing date.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond standard securities law disclaimers. The primary contingency noted is the reliance on the full text of the Underwriting Agreement and Warrants, which are filed as exhibits. The press release announcing the pricing is incorporated by reference.
Investor Verification Checklist
- Verify the net proceeds after deducting underwriting discounts and offering expenses, as only gross proceeds ($10 million) are stated.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific indemnification clauses and termination rights.
- Confirm the dilution impact of the 588,235 underwriter warrants and the 5,882,353 new shares on existing shareholders.
- Check the Company's cash position prior to this offering to assess the immediate liquidity improvement.
- Monitor compliance with the 180-day lock-up period for insiders and the 12-month restriction on variable rate transactions.